CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology…
Continues to interact with FDA regarding orphan drug review of the NDA for Libervant™ (diazepam)…
Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and…
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company…
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors…
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics…
PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical…
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a…
Abstracts for the American Association for Cancer Research (AACR) Annual Meeting were released publicly today…
ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
In a Clinical Trials Plenary Session an update of the phase 1/2 study evaluating cord…
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused…
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a…
MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH)…
Posters will feature programs with best-in-class potential including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and…
REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to…
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company…
OSLO, Norway, March 08, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD),…